This combination medication is used to treat a cough and symptoms associated with the common cold, allergies, hay fever, sinusitis and other respiratory illnesses.

Side Effects:

Dizziness, drowsiness, headache, loss of appetite, constipation, nausea or stomach upset may occur the first several days as your body adjusts to the medication.

If any of these effects continue or become bothersome, inform your doctor.

Notify your doctor if you develop chest pain, a rapid pulse, skin rash, mental confusion, hallucinations or breathing trouble while taking this medication.

To avoid dizziness and lightheadedness when rising from a seated or lying position, get up slowly.

Also limit your intake of alcoholic beverages which will aggravate these effects.

Use caution performing tasks requiring alertness if this medication causes you to feel drowsy.

Watch the latest videos on YouTube.com

Precautions:

BThis medication should be used only if clearly needed during pregnancy.

Discuss the risks and benefits with your doctor.

Since small amounts of this medication are found in breast milk, consult your doctor before breast-feeding.

Tell your doctor if you have any pre-existing kidney disease, heart disease, lung disease, asthma, emphysema, high blood pressure, an overactive thyroid, diabetes, depression or if you have a history of drug dependency or any allergies.

Generic Name: Guaifenesin

Entuss 5-300 mg Tablet - Prescription

Codiclear DH 100-5/5 ml Syrup - Prescription

Vortex 100-5/5 ml Syrup - Prescription

Hydrocodone/Guaifenesin 100-5/5 ml Syrup - Prescription

Hydrotuss 100-5/5 ml Syrup - Prescription

Vi-Q-Tuss 100-5/5 ml Syrup - Prescription

Hydro-Tuss 100-5/5 ml Syrup - Prescription

Medcodin 100-5/5 ml Syrup - Prescription

Hydrocodone GF 100-5/5 ml Syrup - Prescription

M-Clear 100-5/5 ml Syrup - Prescription

Hycotuss 100-5/5 ml Syrup - Prescription

03d-0478-c00055-vol3.pdf

Speaking on behalf of the International Guai-Support Group Network (http://www.psha-inc.com/cuai-support/) comprising, at the time of this writing, 1,705 consumers, we protest the FDA's enforcement of very old legislation that fails to protect the public's access to drugs that have been on the market longer than the FDA has been in existence.
This is especially true concerning single ingredient, sustained-release guaifenesin.
When FDA removed pediatric Humibid from the market last October, they left a very vulnerable section of the population with no access to a very necessary drug.

http://www.fda.gov/ohrms/dockets/dailys/03/dec03/122303/03d-0478-c00055-vol3.pdf
If Adams Labs fails financially, Mucinex will disappear, leaving the consumer with no form of sustained-release guaifenesin. guaifenesin, fibromyalgia.

05-13708.pdf

Administration (FDA) is proposing to amend the tentative final monograph (TFM) for over-the-counter (OTC) cough-cold combination drug products to remove the combination of an oral bronchodilator (products containing ephedrine or its salts) and an expectorant, and to reclassify this combination drug product as Category II (not generally recognized as safe and effective for OTC use).

http://www.regulations.gov/fredpdfs/05-13708.pdf
FDA is also proposing to classify the combination of an oral bronchodilator and an oral nasal decongestant as Category II. FDA is issuing this notice of proposed rulemaking after considering data and information on the appropriateness of these combination drug products to treat mild asthma. drug products, proposed rule.

healthcanada.pdf

2) Complaint that Canadian Apothecary was advertising the compounding of specific drugs in the absence of a DIN and establishment license 3) Complaint respecting sale of drugs without DIN's, sale of Schedule F (prescription) drugs without a prescription, and manufacturing of drugs without holding an establishment licence, and without evidence of Good Manufacturing Practices (GMP) compliance.
We ask that you confirm this communication in writing and advise as to the quantities and disposition of affected stock.

We also wish to thank you for the immediate action taken in the form of removal of pertinent sections of the Canadian Apothecary website. drugs, compliance.

guide-ldir_consult_consum-consom_e.pdf

Health Canada, in collaboration with Advertising Standards Canada (ASC), has developed draft Consumer Advertising Guidelines for Marketed Health Products (Guidelines).
They do not apply to advertising of prescription drugs to consumers nor are they intended to propose any regulatory amendments related to the advertising of products to consumers for the treatment, prevention or cure of Schedule A diseases (i.e., cancer, heart disease).
For multiple medicinal ingredients / multiple indication products: At least one clear therapeutic indication for each medicinal ingredient must be presented in the advertisement (equal focus on each therapeutic indication is not required).

http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/advert-publicit/guide-ldir_consult_consum-consom_e.pdf
When described or depicted, directions for use / dosage and administration must be consistent with the TMA. drugs, unacceptable claim.

Adverse%20Drug%20Reaction%20Newsletter%20Archive%202000-2002.pdf

Inhibition of cisapride metabolism by such drug interactions leads to raised cisapride blood levels, which may cause prolongation of the QT interval and ventricular arrhythmias.3 As of Sept. 16, 1999, the Canadian Adverse Drug Reaction Monitoring Program (CADRMP) received 127 reports of suspected adverse drug reactions (ADRs) associated with the use of cisapride; 70 reports were of a serious nature.
As a result of postmarketing surveillance, important changes were introduced in September 1999 to the product monograph, prescribing information and other labelling material.

Gingko biloba: bleeding disorders Reports of prolonged prothrombin times, warfarin drug interactions, increased coagulation time, subcutaneous hematomas, intracranial hemorrhage associated with the use of gingko biloba were submitted to the CADRMP. reports, concomitant.